Key takeaways:

• Eylea HD dosing intervals were extended up to every 20 weeks for patients with wet AMD and DME.
• The approval also updated the Eylea HD label to reflect data from the PHOTON and PULSAR trials.

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced.

The approval, which extended the dosing intervals up to every 20 weeks, also includes an update to the Eylea HD (aflibercept 8 mg, Regeneron) label to include 2-year data from “the pivotal” PULSAR and PHOTON trials, according to a press release.

“The potential for needing only two or three Eylea HD injections a year to manage certain retinal diseases is an exciting advance that could benefit my patients who have been successfully treated for a year, particularly as safety, durability and flexibility continue to be driving forces behind treatment decisions,” Michael A. Klufas, MD, an assistant professor of ophthalmology at Thomas Jefferson University, said in the release.

Read more: FDA approves extension of Eylea HD dosing intervals

Source: Healio